Bacteria Or Actinomycetales Patents (Class 435/7.32)
-
Patent number: 8476028Abstract: There is provided a method for determining whether a subject has a bacterial infection comprising: identifying an abnormal expression of one or more of CD49e, CD 14, CD11c, CD49f, and CD29 on leucocytes in a sample obtained from the subject; wherein an abnormal expression of CD49e, CD 14, CD11c, CD49f or CD29 is indicative of the subject having a bacterial infection.Type: GrantFiled: January 3, 2012Date of Patent: July 2, 2013Assignee: King's College LondonInventors: Kenneth Alun Brown, Sion Marc Lewis
-
Patent number: 8476032Abstract: Assays for detection of bactericidal anti-Neisserial antibodies using a factor H polypeptide having a human amino acid sequence that mediates binding to Neisserial factor H binding protein (fHBp) are provided, as well as non-human animal models of Neisserial infection.Type: GrantFiled: August 26, 2009Date of Patent: July 2, 2013Assignees: Children's Hospital & Research Center Oakland, Novartis Vaccines and Diagnostics, SRL, The University of MassachusettsInventors: Dan M. Granoff, JoAnne Welsch, Sanjay Ram
-
Patent number: 8475803Abstract: The invention relates to the identification of mycobacterial antigens which are highly immunogenic and which may be used in assays and methods for the diagnosis of tuberculosis and the discrimination between infected animals and animals previously exposed to vaccines.Type: GrantFiled: May 2, 2006Date of Patent: July 2, 2013Assignee: Fusion Antibodies LimitedInventors: Shane A. Olwill, Richard J. Buick, Hangfai Kwok, James A. Johnston
-
Patent number: 8476082Abstract: Devices and methods for the detection of target molecules are disclosed. Devices and methods for detecting food-borne target molecules are also disclosed.Type: GrantFiled: April 12, 2012Date of Patent: July 2, 2013Assignee: Invisible Sentinel, Inc.Inventors: Nicholas A. Siciliano, Martin Joseph Bouliane
-
Publication number: 20130156696Abstract: The invention described herein provides for human antibodies produced in non-human animals that specifically bind to Pseudomonas aeruginosa Lipopolysaccharide (LPS). The invention further provides methods for making the antibodies in a non-human animal, expression of the antibodies in cell lines including hybridomas and recombinant host cell systems. Also provided are kits and pharmaceutical compositions comprising the antibodies and methods of treating or preventing pseudomonas infection by administering to a patient the pharmaceutical compositions described herein.Type: ApplicationFiled: May 27, 2011Publication date: June 20, 2013Applicant: CASE WESTERN RESERVE UNIVERSITYInventors: John R. SCHREIBER, Kulwant KAUR
-
Publication number: 20130157256Abstract: The invention relates to a method for determining the presence of an analyte by means of a distribution of small magnetic particles. According to said method, the magnetisations of the small particles are oriented in relation to each other by means of an outer magnetic focusing field; once the focussing field has been terminated, the magnetisations of the small particles are rotated asynchronously to the magnetic field by means of an outer magnetic field of suitable field intensity and rotational frequency, which rotates about a longitudinal axis (z); the temporal course of the superpositioned transverse magnetisation of the set of particles is detected; and the presence of the analyte is deduced from the detected temporal course. The invention also relates to a corresponding device (1).Type: ApplicationFiled: April 1, 2011Publication date: June 20, 2013Applicants: JULIUS-MAXIMILIANS-UNIVERSITAET WUERZBURG, HOCHSCHULE FUER ANGEWANDTE WISSENSCHAFTENInventors: Martin Rueckert, Volker C. Behr, Thomas Kampf
-
Patent number: 8460879Abstract: Arrays of single molecules and methods of producing an array of single molecules are described. Arrays with defined volumes between 10 attoliters and 50 picoliters enable single molecule detection and quantitation.Type: GrantFiled: February 16, 2007Date of Patent: June 11, 2013Assignee: The Trustees of Tufts CollegeInventors: David R. Walt, David M. Rissin
-
Patent number: 8460878Abstract: Arrays of single cells and methods of producing an array of single cells are described. Arrays with defined volumes between 10 attoliters and 50 picoliters enable single cell capture, detection and quantitation.Type: GrantFiled: February 16, 2007Date of Patent: June 11, 2013Assignee: The Trustees of Tufts CollegeInventors: David R. Walt, David M. Rissin
-
Publication number: 20130142803Abstract: The invention described herein relates to a Haemophilus influenzae (H. influenzae) regulon encoding type IV pili. In particular, the invention relates to type IV pili from nontypeable H. influenzae (NTHi) and from H. influenzae strains a, b, c, e and f. The invention provides isolated H. influenzae pilus polynucleotides and polypeptides encoded by the polynucleotides as well as polynucleotides and polypeptides encoded by the polynucleotides involved in the assembly/disassembly of the structure. The invention also relates to uses of these polynucleotides and/or polypeptides including methods for eliciting an immune response to H. influenzae and methods of treating and preventing H. influenzae related pathological conditions.Type: ApplicationFiled: February 13, 2013Publication date: June 6, 2013Applicant: Nationwide Children's Hospital, Inc.Inventor: Nationwide Children's Hospital, Inc.
-
Patent number: 8455201Abstract: The present invention provides a method for diagnosing a mycobacterial infection in a subject, involving the following steps: (i) collection of a sample from the subject; (ii) incubation of the sample from (i) with an antigen preparation for 12 hours or less; and (iii) analysis of ?-IFN in the sample from (ii). The invention also provides a diagnostic kit for use in such a method.Type: GrantFiled: August 14, 2007Date of Patent: June 4, 2013Assignee: The Pirbright InstituteInventors: Jayne Hope, Paul Sopp, Chris Howard
-
Patent number: 8455210Abstract: The present invention relates to a method for the selective identification of Chlamydia trachomatis infections wherein the antigens CT017, CT098, CT318-L1 P, CT431-TARP, CT603-TSAP, and CT664 are used for the specific identification of Chlamydia trachomatis antibodies in samples from mammals. The method according to the invention facilitates the selective identification method of identification of Chlamydia trachomatis infections, in which no false positive results are generated by other Chlamydia species such as, for example, Chlamydia pneumoniae. The invention further relates to a biochip which has the aforementioned Chlamydia trachomatis-specific antigens for the identification of antibodies. The biochip with antigens according to the invention is suitable for multiparameter identification methods in particular.Type: GrantFiled: March 7, 2008Date of Patent: June 4, 2013Assignee: Mikrogen GmbHInventors: Ulrike Simnacher, Vera Forsbach-Birk, Andreas Essig, Klaus-Ingmar Pfrepper
-
Patent number: 8455211Abstract: Disclosed is the use of isolated Ats-1 protein in Anaplasma phagocytophilum in the ELISA detection of Anaplasma pathogen. The recombinant expression of Ats-1 and its use as a kit for ELISA are also disclosed.Type: GrantFiled: June 22, 2011Date of Patent: June 4, 2013Assignee: Medical Diagnostic Laboratories, LLCInventors: Denise Dimitrov, John G. Hoey
-
Patent number: 8455263Abstract: The present invention relates to an assay device and a method for using such for the quantitative determination of an analyte, based on a test strip, which contains a porous test membrane allowing for capillary flow of the analyte and complexes of the analyte, a porous upstream membrane in fluid connection with the test membrane and a porous downstream membrane in fluid connection with the test membrane, wherein the test membrane contains a test site having immobilized thereon a ligand capable of reacting with the analyte and binding such to the test site, and two standard band sites having immobilized thereon known high and low concentrations of a calibrator agent capable of reacting with a label conjugate and binding such to the standard sites, wherein the upstream membrane has a site for the application of a sample to be analyzed, and has a site downstream from the sample application site for depositing label conjugates capable of reacting with the analyte and label conjugates capable of reacting with theType: GrantFiled: December 30, 2008Date of Patent: June 4, 2013Inventor: Jin Po Lee
-
Publication number: 20130130281Abstract: Accurate and fast detection of the presence of Clostridium difficile (C. difficile) disease is crucial for the proper treatment of patients with C. difficile infection. Present tests detecting the presence of C. difficile disease are fast and cost effective, but are not very sensitive. Using an ELISA including Cell Wall Protein 84 (Cwp84) increases the sensitivity of the ELISA. Cwp84 may be used alone or in combination with other markers to support a diagnosis of C. difficile-associated disease.Type: ApplicationFiled: September 25, 2012Publication date: May 23, 2013Applicant: TECHLAB, INC.Inventor: TECHLAB, INC.
-
Patent number: 8445293Abstract: The present invention includes methods and devices for preventing interfering substances from affecting the accuracy of a lateral flow immunoassay. In preferred embodiments, a test strip includes a capturing zone that includes at least one mobile capturing reagent that separates at least one interfering substance from the analyte. The capturing zone is preferably located upstream of the sample application zone. In some embodiments, the reagent/conjugate zone is also located upstream of the sample application zone. The capturing zone may be located upstream, downstream, or overlapping with the reagent/conjugate zone in these embodiments. In other preferred embodiments, one or more mobile capturing reagents are included in the elution medium/running buffer. In yet other embodiments, the capturing reagent is incorporated into a sample collection device of a sample collection system, preferably separate from the chromatographic test strip. A lysis zone is also included in some preferred embodiments.Type: GrantFiled: September 29, 2009Date of Patent: May 21, 2013Assignee: Rapid Pathogen Screening, Inc.Inventors: Uma Mahesh Babu, Franz Aberl, Marcus Scheibenzuber, Robert P. Sambursky, Robert W. VanDine, Jose S. Sambursky
-
Publication number: 20130115624Abstract: Disclosed are compounds that activate the human G-protein coupled receptor TAS2R41, and methods of using these compounds for identifying compounds that modulate the response of the TAS2R41 receptor. Compounds identified as modulators of the response of the receptor TAS2R41 may be used to decrease or mask the bitter taste of foods or drugs.Type: ApplicationFiled: May 6, 2011Publication date: May 9, 2013Applicant: Givaudan S.A.Inventors: Jay Patrick Slack, Jenny Ellen Evans Pennimpede
-
Patent number: 8431354Abstract: RP-factors, their cognate receptors, convertases, respective genes and inhibitors or mimetics thereof are described. In particular, antibodies, pharmaceutical compositions and (therapeutic, diagnostic) methods based on the RP-factors and their receptors/convertases are described.Type: GrantFiled: June 3, 1998Date of Patent: April 30, 2013Assignee: Aberystwyth UniversityInventors: Galina V Mukamolova, Arseny S Kaprelyants, Danielle I Young, Douglas B Kell, Michael Young
-
Patent number: 8431351Abstract: This invention provides a immunochromatography detection device that can detect PBP2? produced specifically by a bacterium of multidrug-resistant staphylococcus with high sensitivity in a simple and rapid manner via immunochromatography detection to determine infection with multidrug-resistant staphylococcus, a diagnostic method using such detection device, and a diagnostic kit comprising such detection device.Type: GrantFiled: September 9, 2011Date of Patent: April 30, 2013Assignee: Denka Seiken Co., Ltd.Inventor: Hiromi Ito
-
Publication number: 20130102491Abstract: A method for the diagnosis of a tuberculosis infection caused by Mycobacteria belonging to the Mycobacteria tuberculosis complex group (MTC) in an animal including a human being, which comprises in vitro-detection of cell-mediated immune response to OmpAtb and/or antibodies against OmpAtb in a sample taken from that animal.Type: ApplicationFiled: December 18, 2012Publication date: April 25, 2013Applicant: PRIONICS AGInventor: Prionics AG
-
Patent number: 8420340Abstract: Antibodies, polypeptides, and polynucleotides are provided for the detection, prevention, amelioration and treatment of diseases caused by Actinobacillus actinomycetemcomitans.Type: GrantFiled: May 20, 2011Date of Patent: April 16, 2013Assignee: University of Florida Research FoundationInventors: Martin Handfield, Jeffrey Daniel Hillman, Ann Progulske-Fox
-
Publication number: 20130089854Abstract: A kit for dot immunogold directed filtration assay including a dot immunogold directed filtration card, a detection probe labeled by nano colloidal gold or latex beads, a negative standard, a positive standard, and a cleaning solution.Type: ApplicationFiled: December 10, 2010Publication date: April 11, 2013Applicant: XIAN WEITONG BIOSCIENCE LIMITED COMPANYInventor: Yuan Lin
-
Publication number: 20130085076Abstract: The invention relates to both a sensitive method for the capture and detection of low-abundance Borrelia burgdorferi (Bb) bacterial antigens allowing for the diagnosis of Lyme Disease using standard immunoassays. Furthermore, this invention allows the antigen to be identified in a sample of urine, serum, or other biological fluids isolated from humans and animals. The invention provides a method to capture, concentrate, separate and specifically quantify the abundance of Bb antigens using immunoassays. The detection of Bb Outer Surface Protein A is presented as an example of the disclosed invention. High sensitivity levels, low cost and easily collected biofluids allow this technology to reach patients in clinics as well as POC applications for the early detection of Lyme disease prior to seroconversion. A kit containing necessary reagents and the method for diagnosis, monitoring or assessing lyme disease using an immunoassay such as an ELISA, western blot or RPPMA is disclosed.Type: ApplicationFiled: December 1, 2010Publication date: April 4, 2013Inventors: Temple Douglas, Alessandra Luchini, Claudia Fredolini, Davide Tamburro, Lance Liotta
-
Patent number: 8394325Abstract: Methods and devices for reducing interference from leukocytes in an analyte immunoassay are provided. In one embodiment, a method is provided comprising the steps of amending a biological sample with magnetic sacrificial beads opsonized to leukocytes, binding leukocytes in the sample to the magnetic sacrificial beads, and magnetically retaining the beads out of contact from an immunosensor.Type: GrantFiled: June 14, 2010Date of Patent: March 12, 2013Assignee: Abbott Point of Care Inc.Inventors: John Lewis Emerson Campbell, Graham Davis
-
Patent number: 8389293Abstract: The invention is directed to methods and devices for reducing interference from leukocytes in competitive analyte immunoassays. In one embodiment, the invention is to a method comprising the steps of (a) amending a biological sample such as a whole blood sample with sacrificial beads opsonized for leukocytes; and (b) performing a competitive immunoassay on the amended sample to determine the concentration of said analyte in said sample. Preferably, the sample is amended with IgG-coated sacrificial beads.Type: GrantFiled: November 17, 2009Date of Patent: March 5, 2013Assignee: Abbott Point of Care Inc.Inventors: John Lewis Emerson Campbell, Graham Davis
-
Patent number: 8389233Abstract: Provided are methods for sampling, testing and validating test lots, comprising: assembling a plurality of product portions from each of a plurality of test lots and combining the portions to provide a corresponding set of test lot samples; enriching the test lot samples; removing portions of each enriched sample, and combining the removed portions to provide a modular composite sample; and testing of the modular composite sample, and individual testing of the enriched test lot samples, using at least one suitable detection assay for a target microbe or organism, wherein when such testing is negative all test lots are validated, and wherein when such testing is positive with respect to the modular composite sample, or with respect to an individual enriched test lot sample, individual test lots may nonetheless yet be validated by further testing of a portion of respective initially-negative enriched test lot samples and obtaining negative results.Type: GrantFiled: January 27, 2009Date of Patent: March 5, 2013Assignee: Institute for Environmental Health, Inc.Inventor: Mansour Samadpour
-
Publication number: 20130052637Abstract: Compounds and methods are disclosed that are useful for noninvasive imaging in the near-infrared (NIR) spectral range. The NIR is highly sensitive for tumor detection and tracking. The application discloses targeting a tumor-enriched cell surface receptor with a ligand-conjugated fluorescent probe, which specifically allows detection of the tumor relative to the negligible animal autofluorescence.Type: ApplicationFiled: August 29, 2012Publication date: February 28, 2013Applicant: LI-COR, INC.Inventors: Joy Kovar, Jiyan Chen, Daniel R. Draney, D. Michael Olive, William M. Volcheck, Xinshe Xu, Ananda G. Lugade, Narasimhachari Narayanan
-
Publication number: 20130053277Abstract: Methods of identifying inhibitors of polypeptide-of-interests are provided.Type: ApplicationFiled: May 4, 2011Publication date: February 28, 2013Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Inventor: Isaiah Arkin
-
Patent number: 8383353Abstract: Method for in vitro detection and/or quantification and/or identification of bacteria present in a fluid medium M constituting a biological material, in which method a suspension of microbeads of solid polymer material capable of binding proteins is prepared; the microbeads are loaded with ?2GPI proteins; said loaded microbeads are brought into contact with the fluid medium M, in the presence of ions of an oxidizing metal, so as to bind the bacteria to the ?2GPI proteins; the microbeads thus prepared are separated from their suspension medium, so as to obtain a residue; and the bacteria of the residue are detected and/or quantified and/or identified.Type: GrantFiled: January 30, 2009Date of Patent: February 26, 2013Assignee: Apoh Technologies SAInventor: Ilias Stefas
-
Patent number: 8383359Abstract: It is disclosed herein that isolated lymphocytes, such as human B-cells and CD4+ T-cell can be used to determine an amount of lymphocyte-associated anthrax lethal toxin activity present. Methods of using isolated lymphocytes to identify anthrax therapeutic agents and to determine the efficacy of a potential anthrax therapeutic are disclosed. Methods are also provided for diagnosing and treating anthrax infections.Type: GrantFiled: September 24, 2010Date of Patent: February 26, 2013Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: David M. Frucht, Hui Fang
-
Patent number: 8378078Abstract: The invention relates to a method for in vitro seriological diagnosis of Whipple's disease, whereby the bacteria responsible for the disease are isolated and established in a culture and brought into contact with the serum or biological fluid of an infected patient. The invention also relates to useful oligonucleotides with a probe and a primer for amplifying, sequencing and detecting the gene rpoB of the bacteria, Tropheryma whippelii.Type: GrantFiled: May 16, 2008Date of Patent: February 19, 2013Assignee: Protisvalor MediterraneeInventors: Didier Raoult, Bernard La Scola, Marie-Laure Birg, Florence Fenollar
-
Patent number: 8377669Abstract: The invention is directed to methods and devices for reducing interference from leukocytes in an analyte immunoassay, and in particular in non-competitive immunoassays. In one embodiment, the invention is to a method comprising the steps of (a) amending a biological sample such as a whole blood sample with sacrificial beads; and (b) performing a non-competitive immunoassay on the amended sample to determine the concentration of said analyte in said sample. Preferably, the sample is amended with IgG-coated sacrificial beads.Type: GrantFiled: November 17, 2009Date of Patent: February 19, 2013Assignee: Abbott Point of Care Inc.Inventors: John Lewis Emerson Campbell, Adam Roger Moss, Graham Davis
-
Patent number: 8377651Abstract: Described herein are methods of detecting an infection and for detecting the presence or absence of microorganisms, for example, wound pathogens in a sample, by contacting a sample with an enzyme produced and/or secreted by the bacteria, and detecting modification or the absence of modification of the substrate, as an indicator of the presence or absence of the enzyme in the sample. The present invention also features a biosensor for detecting the presence or absence of bacteria in a sample.Type: GrantFiled: September 30, 2010Date of Patent: February 19, 2013Assignee: Systagenix Wound Management (US), Inc.Inventors: Gerard J. Colpas, Diane Ellis-Busby, Shite Sebastian, Mitchell C. Sanders
-
Publication number: 20130029356Abstract: Methods and systems for using drugs as biomarkers to investigate the status of biological systems are disclosed. A drug is conjugated with a light emitting dye that emits light in a channel of the electromagnetic spectrum when an appropriate stimulus is applied. In one aspect, a suspension suspected of containing target particles is added to a tube along with the conjugated drug/dye complex and a float. Centrifugation of the tube, float, and suspension causes various components to separate along the axial length of the tube. Binding of the drug/dye complex to the target particles can be assessed by applying an appropriate stimulus to the tube, which, in turn, causes the fluorescent dyes to emit light in the channel. The level of fluorescence of the target particles located between the float and the inner wall of the tube can be used to assess use of the drug in therapy.Type: ApplicationFiled: July 26, 2012Publication date: January 31, 2013Inventor: Jackie L. Stilwell
-
Patent number: 8361737Abstract: The invention is a herd management schema based upon the inventor's analysis of the natural history of bovine infection due to Mycobacterium avium subspecies paratuberculosis (Map) and related genomic variants and upon the ability of two distinct Map ELISA tests to sequentially or in parallel determine prior and current Map infection and evidence of active mycobacterium replication. Interpretation of the test results are integrated into sequential directives designed to enhance productive retention of infected animals as well as identify animals not previously infected. The sequential utilization of the data guidelines is developed to minimize the adverse economic impact.Type: GrantFiled: March 8, 2012Date of Patent: January 29, 2013Inventor: Gilles R. G. Monif
-
Patent number: 8361707Abstract: Methods for detecting an infection with Mycobacterium tuberculosis (Mtb) in a subject are disclosed. The methods include detecting the presence of CD8+ T cells that specifically recognize an Mtb polypeptide. The methods include in vitro assays for detecting the presence of CD8+ T cells in a biological sample, and in vivo assays that detect a delayed type hypersensitivity reaction. The methods can also include detecting Mtb polypeptides and polynucleotides. Reagents for the detection of an Mtb infection are also disclosed.Type: GrantFiled: September 23, 2011Date of Patent: January 29, 2013Assignees: Oregon Health & Science University, The United States of America, Department of Veterans AffairsInventors: David M. Lewinsohn, Deborah A. Lewinsohn
-
Publication number: 20130017204Abstract: The invention relates to the polynucleotide sequence of a nontypeable stain of Haemophilus influenzae (NTHi) and polypeptides encoded by the polynucleotides and uses thereof. The invention also relates to NTHi genes which are upregulated during or in response to NTHi infection of the middle ear and/or the nasopharynx.Type: ApplicationFiled: July 19, 2012Publication date: January 17, 2013Applicants: THE BOARD OF REGENTS OF UNIVERSITY OF OKLAHOMA, NATIONWIDE CHILDREN'S HOSPITAL, INC.Inventors: Lauren O. Bakaletz, Robert S. Munson, JR., David W. Dyer
-
Patent number: 8354240Abstract: The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic Borreliae, the use of the DNA sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the DNA and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the detection of organisms causing Lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, DNA segments and antibodies.Type: GrantFiled: December 5, 2011Date of Patent: January 15, 2013Assignee: Board of Regents, The University of Texas SystemInventors: Steven J. Norris, Jing-Ren Zhang, John M. Hardham, Jemlyn K. Howell, Alan G. Barbour, George M. Weinstock
-
Publication number: 20130011862Abstract: The present invention relates to processes for the rapid detection, semi-quantification and quantification of live microorganisms in solutions or suspensions using immunomagnetic particles, without requiring pre-enrichment through culture of the microorganism. The invention also relates to kits for carrying out said processes and to the quantification of the microorganisms detected by means of automated biosensor equipment.Type: ApplicationFiled: November 14, 2011Publication date: January 10, 2013Applicant: BIOTICA, BIOQUIMICA ANALITICA, S.L.Inventors: Guillermo RODRIGUEZ ALBALAT, Maria Luisa JIMENEZ BONO, Daniel CANOS MARTI
-
Patent number: 8349570Abstract: Provided herein are methods for detecting gram negative bacteria or lipopolysaccharide in a sample. Kits for detecting gram negative bacteria or lipopolysaccharide in a sample are provided.Type: GrantFiled: September 13, 2010Date of Patent: January 8, 2013Assignee: BioDtech, Inc.Inventors: Michael G. Pepe, Milton Keith Champion
-
Patent number: 8343507Abstract: A derivative of a 55 kDa extracellular protein from Photobacterium damselae subsp. piscicida is the basis for a vaccine against Photobacterium infection, and thereby protects fish from pasteurellosis.Type: GrantFiled: June 11, 2012Date of Patent: January 1, 2013Assignee: Novartis AGInventors: Nuno Miguel Simoes Dos Santos, Ana Maria Silva Do Vale, Manuel Alexandre Teixera Da Silva, Jorge Eduardo Da Silva Azevedo
-
Patent number: 8343726Abstract: The present invention provides assays and devices for detection of substances in liquid samples. The assays and devices utilize passive diffusion between a porous material and a porous membrane containing a specific binding pair member to enable detection of the substance of interest.Type: GrantFiled: November 23, 2005Date of Patent: January 1, 2013Assignee: Techlab, Inc.Inventors: James H. Boone, David M. Lyerly, Tracy D. Wilkins
-
Publication number: 20120315278Abstract: Described are human binding molecules specifically binding to enterococci and having killing activity against enterococci, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The molecules can be used in the diagnosis, prophylaxis, and/or treatment of a condition resulting from Enterococcus.Type: ApplicationFiled: July 16, 2012Publication date: December 13, 2012Inventors: Mark Throsby, Robert Arjen Kramer, Cornelis Adriaan De Kruif
-
Patent number: 8329418Abstract: Contemplated compositions, devices, and methods are drawn to various antigens from the pathogen M. tuberculosis and their use in vaccines, therapeutic agents, and various diagnostic tests. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and/or have a known association with a disease parameter.Type: GrantFiled: February 14, 2012Date of Patent: December 11, 2012Assignee: ImmportTherapeutics, Inc.Inventors: Philip Felgner, Xiaowu Liang, Maria Laura Gennaro
-
Publication number: 20120302940Abstract: The present invention provides multifunctional popcorn-shaped gold nanomaterial for sensing, treatment and for a unique way of monitoring treatment effectiveness during therapy process of different human cancer cells and pathogenic bacteria. It consists of the following steps 1) Synthesis of popcorn-shaped gold nanoparticles of different sizes. 2) Design of multifunctional popcorn-shaped gold nanoparticle for targeted sensing, therapy and monitoring therapy effectiveness for different human cancer cells (liver, breast, skin and prostate) and drug resistance bacteria. 3) Design of portable SERS sensor for cancer detection, treatment and for monitoring treatment effectiveness using the same instrument. and 4) Application of our approach to detect and kill MDRB from food sample.Type: ApplicationFiled: November 30, 2011Publication date: November 29, 2012Applicant: JACKSON STATE UNIVERSITYInventor: Paresh Chandra Ray
-
Patent number: 8318438Abstract: We describe examples using aptamers for capturing and reporting the presence of a target, such as a pathogen. Examples described here include a set of aptamers that are specific to F. tularensisis. Other examples described here include an Aptamer-Linked Immobilized Sorbent Assay (ALISA) and dot blot assay. An example of a method provided here comprises: providing a set of DNA sequences that exhibit high binding affinity to target antigen, placing the DNA sequences in a sandwich aptamer-linked immobilized sorbent assay (ALISA), contacting the DNA sequences with a sample, and detecting whether the target is present in the sample. Some alternative implementations may include dot blots and different reporters. Quantum dot sandwich assays and quantum dot de-quenching reporters can be used.Type: GrantFiled: February 27, 2008Date of Patent: November 27, 2012Assignee: The United States of America as represented by the Secretary of the Air ForceInventors: Jeevalatha Vivekananda, Johnathan L. Kiel
-
Patent number: 8318445Abstract: The present invention relates to methods and systems for labeling, isolating, detecting, and/or enumerating a statistically significant number of biological cells, or other biological analytes of interest, present in a complex matrix sample. The isolation of a biological target of interest from a sample mixture is done by immunomagnetic separation. Upon introduction of the sample within an imaging chamber, the capture complex (biological target-magnetic capture agent) will be attracted by the magnetic field and will lay on the surface of the chamber in the focal plane of the imaging system.Type: GrantFiled: January 7, 2009Date of Patent: November 27, 2012Assignee: Luminex CorporationInventors: Bruce J-C Bernard, Kurt D. Hoffacker, Charles J. Collins
-
Publication number: 20120282635Abstract: A method and apparatus for measuring antibody titers in a thin film sample in an automated system which does not require multiple dilutions. The system provides a simple method for creating an in-situ dilution within a sample analysis chamber without the use of any precision fluid-handling components, and further, to use the same principles to provide a wide range of sample dilutions within the chamber so as to obviate the need for additional dilution steps when dealing with samples possibly containing wide ranges of analyte concentrations.Type: ApplicationFiled: July 16, 2012Publication date: November 8, 2012Applicant: ABBOTT POINT OF CARE, INC.Inventors: Stephen C. Wardlaw, Robert A. Levine
-
Publication number: 20120276120Abstract: Polypeptides that can elicit antibodies that bind to T-cell stimulating protein B (TspB) of N. meningitidis, and methods of use, are provided.Type: ApplicationFiled: November 4, 2010Publication date: November 1, 2012Inventor: Gregory R. Moe
-
Patent number: 8298778Abstract: A method and a kit for detecting an antibody to Avibacterium paragallinarum are provided. A method for detecting an antibody to Avibacterium paragallinarum which comprises detecting an antibody induced by an outer-membrane protein of Avibacterium paragallinarum serotype A and/or serotype C by ELISA with a solid phase to which a peptide consisting of an amino acid sequence of non-homologous region of said outer-membrane protein or a portion thereof is immobilized, and a detection kit used for said method.Type: GrantFiled: February 6, 2009Date of Patent: October 30, 2012Assignee: The Chemo-Sero-Therapeutic Research InstituteInventors: Toshihiro Ushijima, Takashi Imamura, Ryuichi Sakamoto, Masashi Sakaguchi
-
Publication number: 20120270236Abstract: Nucleic acid and protein sequences relating to a proton channel (HvI) are disclosed. Nucleic acids, vectors, transformed cells, transgenic animals, polypeptides, and antibodies relating to the HvI gene and protein are disclosed. Also provided are methods of identifying modulators of HvI activity, methods of geno typing subjects with respect to HvI, and methods of diagnosing and treating HvI-mediated disorders.Type: ApplicationFiled: February 15, 2007Publication date: October 25, 2012Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Ian S. Ramsey, Magdalene M. Moran, Jayhong A. Chong, David Clapham